-
Current Pharmaceutical Design 2023
Topics: Humans; Antineoplastic Agents; Neoplasms
PubMed: 37655591
DOI: 10.2174/138161282922230822111237 -
Nature Reviews. Microbiology Dec 2022
Topics: Antineoplastic Agents; Gastrointestinal Microbiome; Neoplasms
PubMed: 36224380
DOI: 10.1038/s41579-022-00812-y -
Postepy Biochemii 2002
Review
Topics: Acetylation; Animals; Antineoplastic Agents; Humans; Quinazolines
PubMed: 12101524
DOI: No ID Found -
Phytotherapy Research : PTR Feb 2024Natural products have played a significant role throughout history in the prevention and treatment of numerous diseases, particularly cancers. As a natural product... (Review)
Review
Natural products have played a significant role throughout history in the prevention and treatment of numerous diseases, particularly cancers. As a natural product primarily derived from various medicinal plants in the Withania genus, withanolides have been shown in several studies to exhibit potential activities in cancer treatment. Consequently, understanding the molecular mechanism of withanolides could herald the discovery of new anticancer agents. Withanolides have been studied widely, especially in the last 20 years, and attracted the attention of numerous researchers. Currently, over 1200 withanolides have been classified, with approximately a quarter of them having been reported in the literature to be able to modulate the survival and death of cancer cells through multiple avenues. To what extent, though, has the anticancer effects of these compounds been studied? How far are they from being developed into clinical drugs? What are their potential, characteristic features, and challenges? In this review, we elaborate on the current knowledge of natural compounds belonging to this class and provide an overview of their natural sources, anticancer activity, mechanism of action, molecular targets, and implications for anticancer drug research. In addition, direct targets and clinical research to guide the design and implementation of future preclinical and clinical studies to accelerate the application of withanolides have been highlighted.
Topics: Humans; Withanolides; Antineoplastic Agents; Neoplasms; Withania; Plants, Medicinal
PubMed: 38176694
DOI: 10.1002/ptr.8090 -
The Oncologist Mar 2019It is common for patients to have limited access to oral antineoplastics or to discontinue treatment because of cost. Such oral treatments are also discontinued because...
It is common for patients to have limited access to oral antineoplastics or to discontinue treatment because of cost. Such oral treatments are also discontinued because of toxicity, disease progression, or death, resulting in unused portions of these medications. Policies for the subsequent use or destruction of unused drugs exist, but none completely address the need for methods of recycling back to the patients in need. This article addresses this wastefulness and ways to minimize it so that more patients benefit.
Topics: Administration, Oral; Antineoplastic Agents; Humans
PubMed: 30568023
DOI: 10.1634/theoncologist.2018-0565 -
Clinical Techniques in Small Animal... May 2003Chemotherapeutic agents can be used to increase both the length and the quality of the lives of patients with a wide variety of neoplastic diseases. The therapeutic... (Review)
Review
Chemotherapeutic agents can be used to increase both the length and the quality of the lives of patients with a wide variety of neoplastic diseases. The therapeutic index for many of these agents is very narrow; thus, close attention must be paid to proper dosing and timing of treatment. Proper patient selection is also critical for successful chemotherapy treatment. If the clinician is familiar with the agents being used, then toxicities can often be anticipated and then treated, or in some cases prevented, to ensure continued quality of life. The purpose of this article is to review the basic principles for the safe and effective use of various chemotherapeutic agents in the treatment of neoplastic diseases.
Topics: Animals; Antineoplastic Agents; Neoplasms; Veterinary Medicine
PubMed: 12831063
DOI: 10.1053/svms.2003.36617 -
Cancer Chemotherapy and Biological... 2005
Review
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Enzyme Inhibitors; Etoposide; Humans; Neoplasms; Topoisomerase II Inhibitors
PubMed: 16110609
DOI: 10.1016/s0921-4410(04)22005-1 -
International Journal of Molecular... Mar 2022The research interest in the field of inorganic medicinal chemistry had a large increase after the serendipitous discovery of the cytotoxic activity of cisplatin by...
The research interest in the field of inorganic medicinal chemistry had a large increase after the serendipitous discovery of the cytotoxic activity of cisplatin by Rosenberg at the end of 1960s [...].
Topics: Antineoplastic Agents; Cisplatin
PubMed: 35408863
DOI: 10.3390/ijms23073504 -
Seminars in Oncology Apr 2017
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Drug Discovery; Humans; Neoplasms
PubMed: 28923208
DOI: 10.1053/j.seminoncol.2017.06.004 -
Pharmacological Reviews Oct 2019Cancer in children is rare with approximately 15,700 new cases diagnosed in the United States annually. Through use of multimodality therapy (surgery, radiation therapy,... (Review)
Review
Cancer in children is rare with approximately 15,700 new cases diagnosed in the United States annually. Through use of multimodality therapy (surgery, radiation therapy, and aggressive chemotherapy), 70% of patients will be "cured" of their disease, and 5-year event-free survival exceeds 80%. However, for patients surviving their malignancy, therapy-related long-term adverse effects are severe, with an estimated 50% having chronic life-threatening toxicities related to therapy in their fourth or fifth decade of life. While overall intensive therapy with cytotoxic agents continues to reduce cancer-related mortality, new understanding of the molecular etiology of many childhood cancers offers an opportunity to redirect efforts to develop effective, less genotoxic therapeutic options, including agents that target oncogenic drivers directly, and the potential for use of agents that target the tumor microenvironment and immune-directed therapies. However, for many high-risk cancers, significant challenges remain.
Topics: Animals; Antineoplastic Agents; Child; Drug Development; Humans; Neoplasms; Tumor Microenvironment
PubMed: 31558580
DOI: 10.1124/pr.118.016972